161 related articles for article (PubMed ID: 34464933)
1. Therapeutics development for Ebola virus disease: A recent scenario.
Chakraborty C
Curr Opin Pharmacol; 2021 Oct; 60():208-215. PubMed ID: 34464933
[TBL] [Abstract][Full Text] [Related]
2. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
Tshiani Mbaya O; Mukumbayi P; Mulangu S
Front Immunol; 2021; 12():721328. PubMed ID: 34526994
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
Mulangu S; Dodd LE; Davey RT; Tshiani Mbaya O; Proschan M; Mukadi D; Lusakibanza Manzo M; Nzolo D; Tshomba Oloma A; Ibanda A; Ali R; Coulibaly S; Levine AC; Grais R; Diaz J; Lane HC; Muyembe-Tamfum JJ; ; Sivahera B; Camara M; Kojan R; Walker R; Dighero-Kemp B; Cao H; Mukumbayi P; Mbala-Kingebeni P; Ahuka S; Albert S; Bonnett T; Crozier I; Duvenhage M; Proffitt C; Teitelbaum M; Moench T; Aboulhab J; Barrett K; Cahill K; Cone K; Eckes R; Hensley L; Herpin B; Higgs E; Ledgerwood J; Pierson J; Smolskis M; Sow Y; Tierney J; Sivapalasingam S; Holman W; Gettinger N; Vallée D; Nordwall J;
N Engl J Med; 2019 Dec; 381(24):2293-2303. PubMed ID: 31774950
[TBL] [Abstract][Full Text] [Related]
4. REGN-EB3: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):175-178. PubMed ID: 33432551
[TBL] [Abstract][Full Text] [Related]
5. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
6. Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program.
Jaspard M; Juchet S; Serra B; Mayoum B; Kanta IM; Camara MS; Mbala P; Kojan R; Malvy D
Int J Infect Dis; 2021 Dec; 113():166-167. PubMed ID: 34587535
[TBL] [Abstract][Full Text] [Related]
7. Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series.
Ottoni MP; Ricciardone JD; Nadimpalli A; Singh S; Katsomya AM; Pokoso LM; Petrucci R
Lancet Child Adolesc Health; 2020 Dec; 4(12):884-888. PubMed ID: 33217357
[TBL] [Abstract][Full Text] [Related]
8. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus.
Saxena D; Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2021 Aug; 57(8):483-490. PubMed ID: 34405205
[TBL] [Abstract][Full Text] [Related]
9. Ebola Virus Entry Inhibitors.
Du R; Cui Q; Caffrey M; Rong L
Adv Exp Med Biol; 2022; 1366():155-170. PubMed ID: 35412140
[TBL] [Abstract][Full Text] [Related]
10. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Gaudinski MR; Coates EE; Novik L; Widge A; Houser KV; Burch E; Holman LA; Gordon IJ; Chen GL; Carter C; Nason M; Sitar S; Yamshchikov G; Berkowitz N; Andrews C; Vazquez S; Laurencot C; Misasi J; Arnold F; Carlton K; Lawlor H; Gall J; Bailer RT; McDermott A; Capparelli E; Koup RA; Mascola JR; Graham BS; Sullivan NJ; Ledgerwood JE;
Lancet; 2019 Mar; 393(10174):889-898. PubMed ID: 30686586
[TBL] [Abstract][Full Text] [Related]
12. [Virus specific antibody - based remedies for the urgent prevention and treatment of Ebola virus disease].
Sizikova TE; Lebedev VN; Borisevich SV
Ter Arkh; 2019 Nov; 91(11):98-104. PubMed ID: 32598619
[TBL] [Abstract][Full Text] [Related]
13. Perspectives towards antiviral drug discovery against Ebola virus.
Mirza MU; Vanmeert M; Ali A; Iman K; Froeyen M; Idrees M
J Med Virol; 2019 Dec; 91(12):2029-2048. PubMed ID: 30431654
[TBL] [Abstract][Full Text] [Related]
14. Development of therapeutics for treatment of Ebola virus infection.
Li H; Ying T; Yu F; Lu L; Jiang S
Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
[TBL] [Abstract][Full Text] [Related]
15. [The use of monoclonal antibodies for the treatment of Ebola virus disease.].
Sizikova TE; Borisevich GV; Shcheblyakov DV; Burmistrova DA; Lebedev VN
Vopr Virusol; 2018; 63(6):245-249. PubMed ID: 30641019
[TBL] [Abstract][Full Text] [Related]
16. Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease.
Schafer A; Cheng H; Lee C; Du R; Han J; Perez J; Peet N; Manicassamy B; Rong L
Curr Med Chem; 2018; 25(38):5177-5190. PubMed ID: 29032747
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo.
Pessi A; Bixler SL; Soloveva V; Radoshitzky S; Retterer C; Kenny T; Zamani R; Gomba G; Gharabeih D; Wells J; Wetzel KS; Warren TK; Donnelly G; Van Tongeren SA; Steffens J; Duplantier AJ; Kane CD; Vicat P; Couturier V; Kester KE; Shiver J; Carter K; Bavari S
Antiviral Res; 2019 Nov; 171():104592. PubMed ID: 31473342
[TBL] [Abstract][Full Text] [Related]
19. Structure of the Inmazeb cocktail and resistance to Ebola virus escape.
Rayaprolu V; Fulton BO; Rafique A; Arturo E; Williams D; Hariharan C; Callaway H; Parvate A; Schendel SL; Parekh D; Hui S; Shaffer K; Pascal KE; Wloga E; Giordano S; Negron N; Ni M; Copin R; Atwal GS; Franklin M; Boytz RM; Donahue C; Davey R; Baum A; Kyratsous CA; Saphire EO
Cell Host Microbe; 2023 Feb; 31(2):260-272.e7. PubMed ID: 36708708
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein.
Misasi J; Sullivan NJ
Immunity; 2021 Mar; 54(3):412-436. PubMed ID: 33691133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
